Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Immunoglobulin Deficiency”

291 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 291 results

Early research (Phase 1)Study completedNCT03961438
What this trial is testing

Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine

Who this might be right for
HIV-1-infection
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 24
Testing effectiveness (Phase 2)Ended earlyNCT02355184
What this trial is testing

An Extension of Protocol PRO 140_CD01 Study

Who this might be right for
HIVHuman Immunodeficiency Virus
CytoDyn, Inc. 20
Large-scale testing (Phase 3)Study completedNCT00168025
What this trial is testing

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Who this might be right for
AgammaglobulinemiaIgG DeficiencyCommon Variable Immunodeficiency
CSL Behring 89
Large-scale testing (Phase 3)Active Not RecruitingNCT04565015
What this trial is testing

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Who this might be right for
Primary Immune Deficiency
GC Biopharma Corp 24
Not applicableStudy completedNCT06150534
What this trial is testing

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

Who this might be right for
Primary Immunodeficiency Diseases (PID)
Takeda 22
Large-scale testing (Phase 3)Study completedNCT00538915
What this trial is testing

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Who this might be right for
Primary Immune Deficiency Disorders (PIDD)
ADMA Biologics, Inc. 63
Early research (Phase 1)Study completedNCT02165267
What this trial is testing

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 88
Post-approval studies (Phase 4)Study completedNCT02711228
What this trial is testing

Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

Who this might be right for
Primary Immune DeficiencySecondary Immune Deficiency
CSL Behring 26
Not applicableLooking for participantsNCT06497829
What this trial is testing

Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency

Who this might be right for
Mevalonate Kinase Deficiency
University Hospital, Motol 6
Post-approval studies (Phase 4)Ended earlyNCT02659761
What this trial is testing

Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs

Who this might be right for
Human Immunodeficiency Virus
University College Dublin 33
Early research (Phase 1)Study completedNCT01993706
What this trial is testing

Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults

Who this might be right for
HIV InfectionMonoclonal Antibody, HumanHIV Antibodies+2 more
National Institute of Allergy and Infectious Diseases (NIAID) 29
Not applicableStudy completedNCT02190578
What this trial is testing

Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test

Who this might be right for
HIV Infections
MedMira Laboratories Inc. 1,649
Large-scale testing (Phase 3)Study completedNCT00168012
What this trial is testing

Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

Who this might be right for
AgammaglobulinemiaIgG DeficiencyCommon Variable Immunodeficiency
CSL Behring 42
Early research (Phase 1)Study completedNCT01127464
What this trial is testing

DCVax Plus Poly ICLC in Healthy Volunteers

Who this might be right for
HIV-1 InfectionHIV InfectionHealthy Volunteers
Rockefeller University 43
Large-scale testing (Phase 3)Study completedNCT00220766
What this trial is testing

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Who this might be right for
Immunologic Deficiency SyndromeAgammaglobulinemiaSevere Combined Immunodeficiency+2 more
Grifols Therapeutics LLC 100
Not applicableLooking for participantsNCT06989541
What this trial is testing

Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy

Who this might be right for
Hypogammaglobulinemia, Acquired
University of Alberta 30
Large-scale testing (Phase 3)Study completedNCT00000751
What this trial is testing

A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)

Who this might be right for
HIV InfectionsPregnancy
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 1,600
Not applicableStudy completedNCT03401268
What this trial is testing

Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients

Who this might be right for
Hypogammaglobulinemia
University Health Network, Toronto 20
Early research (Phase 1)Study completedNCT02463227
What this trial is testing

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 14
Post-approval studies (Phase 4)Study completedNCT04566692
What this trial is testing

Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

Who this might be right for
Primary Immunodeficiency
Grifols Therapeutics LLC 33
Load More Results